Research directory

Clinical trials for IBD

Below are clinical trials currently recruiting participants in the United States.

125 studies

Duvakitug Maintenance Study for Moderately to Severely Active Ulcerative Colitis

Phase 3 study of duvakitug maintenance treatment in people with moderately to severely active ulcerative colitis who completed qualifying prior studies.

Ulcerative Colitis

Phase: Phase 3
Age range: 16 Years–80 Years
Enrollment: 751 participants

46 recruiting sites

Updated Aug 18, 2026

Recruiting

NCT07686081

Phase 3 Study of Ponesimod for Moderately to Severely Active Ulcerative Colitis

A Phase 3 study comparing ponesimod with placebo in adults with moderately to severely active ulcerative colitis.

Ulcerative Colitis (UC)

Phase: Phase 3
Age range: 18 Years–75 Years
Enrollment: 150 participants

2 recruiting sites

Updated Aug 18, 2026

Recruiting

NCT07769437

Sucralose and Gut Microbiota in Adults With Crohn’s Disease and Healthy Controls

This study examines how sucralose affects gut microbiota in adults with Crohn’s disease and healthy adults without inflammatory bowel disease.

Crohn Disease (CD) · Inflamatory Bowel Disease

Phase: Na
Age range: 18 Years–70 Years
Enrollment: 40 participants

3 recruiting sites

Updated Aug 18, 2026

Recruiting

NCT06581328

Vedolizumab for Adults With Active Ulcerative Colitis or Crohn's Disease

A Phase 4 study of vedolizumab in adults with moderately to severely active ulcerative colitis or Crohn's disease.

Crohn's Disease · Ulcerative Colitis

Phase: Phase 4
Age range: 18 Years–80 Years
Enrollment: 400 participants

77 recruiting sites

Updated Aug 14, 2026

Recruiting

NCT07158242

Phase 3 Afimkibart Study for Children With Moderate to Severe Ulcerative Colitis

A Phase 3 study of afimkibart in children ages 2–17 with moderately to severely active ulcerative colitis.

Moderately to Severely Active Ulcerative Colitis

Phase: Phase 3
Age range: 2 Years–17 Years
Enrollment: 100 participants

22 recruiting sites

Updated Aug 14, 2026

Recruiting

NCT06045754

Dual Targeted Drug Therapy for Adults With Moderate to Severe Crohn’s Disease

A phase 4 study of vedolizumab combined with adalimumab or ustekinumab in adults with moderate to severe Crohn’s disease.

Crohn's Disease

Phase: Phase 4
Age range: 18 Years–70 Years
Enrollment: 100 participants

48 recruiting sites

Updated Aug 12, 2026

Recruiting

NCT06095128

Vedolizumab With Tofacitinib for Adults With Active Ulcerative Colitis

This study tests vedolizumab with tofacitinib in adults with moderately to severely active ulcerative colitis.

Ulcerative Colitis

Phase: Phase 4
Age range: 18 Years–65 Years
Enrollment: 65 participants

46 recruiting sites

Updated Aug 12, 2026

Recruiting

NCT06512597

Coping-Skills Therapy With Biologic Treatment for Active Crohn’s Disease

A randomized study of coping-skills therapy alongside new biologic treatment in adults with recently diagnosed, active Crohn’s disease.

Crohn's Disease

Phase: Na
Age range: 18 Years–65 Years
Enrollment: 170 participants

2 recruiting sites

Updated Aug 12, 2026

Recruiting

NCT07034443

Electromagnetic Stimulation for Fecal Incontinence After J-Pouch Surgery

This pilot study evaluates electromagnetic stimulation in adults with fecal incontinence after J-pouch surgery for ulcerative colitis or IBD-unclassified.

Fecal Incontinence

Phase: Na
Age range: 18 Years and older
Enrollment: 20 participants

1 recruiting site

Updated Aug 12, 2026

Recruiting

NCT05867329

Adaptive Hospital Drug Strategies for Acute Severe Ulcerative Colitis

A randomized pilot tests adaptive hospital drug strategies for adults ages 18 to 75 with acute severe ulcerative colitis.

Ulcerative Colitis Acute

Phase: Phase 4
Age range: 18 Years–75 Years
Enrollment: 700 participants

1 recruiting site

Updated Aug 11, 2026

Recruiting

NCT07298421

Afimkibart for Children With Moderately to Severely Active Crohn's Disease

A phase 3 study of afimkibart in children ages 2–17 with moderately to severely active Crohn's disease.

Moderately to Severely Active Crohns Disease

Phase: Phase 3
Age range: 2 Years–17 Years
Enrollment: 100 participants

10 recruiting sites

Updated Aug 10, 2026

Recruiting

NCT05230173

Switching or Continuing IBD Therapy Despite Ongoing Bowel Inflammation

A randomized study compares switching versus continuing targeted therapy in adults with symptom-free but endoscopically active Crohn’s disease or ulcerative colitis.

Crohn Disease · Ulcerative Colitis

Phase: Na
Age range: 18 Years and older
Enrollment: 216 participants

19 recruiting sites

Updated Aug 7, 2026

Recruiting

NCT06571669

Sacral Neuromodulation for Bowel Urgency in Adults With Ulcerative Colitis

A single-group study of implanted sacral neuromodulation for bowel urgency in adults ages 18 to 85 with ulcerative colitis.

Inflammatory Bowel Diseases · Ulcerative Colitis

Phase: Na
Age range: 18 Years–85 Years
Enrollment: 137 participants

17 recruiting sites

Updated Aug 6, 2026

Recruiting

NCT07077746

Donor-Derived Stem Cell Infusions for Adults With Crohn's Disease

A placebo-controlled study of intravenous donor-derived stem cells in 46 adults with mild or moderate Crohn's disease.

Crohn Disease (CD)

Phase: Phase 2
Age range: 18 Years–65 Years
Enrollment: 46 participants

1 recruiting site

Updated Aug 6, 2026

Recruiting

NCT06588855

Phase 3 Study of Afimkibart for Moderately to Severely Active Ulcerative Colitis

A Phase 3 study comparing afimkibart with placebo in people aged 16–80 with moderately to severely active ulcerative colitis.

Moderately to Severely Active Ulcerative Colitis

Phase: Phase 3
Age range: 16 Years–80 Years
Enrollment: 350 participants

163 recruiting sites

Updated Aug 5, 2026

Recruiting

NCT06819891

Afimkibart Induction Therapy for Moderately to Severely Active Crohn’s Disease

Phase III study of afimkibart induction therapy in people aged 16–80 with moderately to severely active Crohn’s disease.

Moderately to Severely Active Crohns Disease

Phase: Phase 3
Age range: 16 Years–80 Years
Enrollment: 425 participants

190 recruiting sites

Updated Aug 4, 2026

Recruiting

NCT04263831

Low-Dose Interleukin-2 for Moderate-to-Severe Crohn’s Disease

A single-group study of low-dose interleukin-2 in people with moderate-to-severe Crohn’s disease.

Crohn Disease

Phase: Phase 1, Phase 2
Age range: 12 Years–80 Years
Enrollment: 30 participants

3 recruiting sites

Updated Aug 3, 2026

Recruiting

NCT06100289

Vedolizumab for children with ulcerative colitis or Crohn's disease

A study of vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease.

Crohn's Disease · Ulcerative Colitis

Phase: Phase 3
Age range: 2 Years–17 Years
Enrollment: 70 participants

29 recruiting sites

Updated Aug 3, 2026

Recruiting

NCT03816345

Nivolumab-Based Cancer Treatment in Adults With Autoimmune Disorders

A phase 1 study of nivolumab-based cancer treatments in adults who have an autoimmune disorder.

Autoimmune Disease · Crohn Disease · Dermatomyositis · Hematopoietic and Lymphoid Cell Neoplasm · Inflammatory Bowel Disease · Malignant Solid Neoplasm · Multiple Sclerosis · Psoriasis · Psoriatic Arthritis · Rheumatoid Arthritis · Sjogren Syndrome · Systemic Lupus Erythematosus · Systemic Scleroderma · Ulcerative Colitis

Phase: Phase 1
Age range: 18 Years and older
Enrollment: 300 participants

41 recruiting sites

Updated Jul 31, 2026

Recruiting

NCT06663332

Long-term Guselkumab Safety in Pediatric Crohn's, Colitis, or Psoriatic Arthritis

A phase 3 extension study assessing long-term guselkumab safety in pediatric participants with Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis.

Arthritis, Juvenile · Arthritis, Psoriatic · Colitis, Ulcerative · Crohns Disease

Phase: Phase 3
Age range: 3 Years and older
Enrollment: 196 participants

49 recruiting sites

Updated Jul 31, 2026